Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Reminder—A link to the latest version of Mufaso’s table on oral weight-loss drugs resides in the Compilations section at the bottom of the main page for the Biotech Values board.
UPDATED 07/07/24-List of ORAL Weight loss candidates.
07/07/2024 Changes
Most Interesting NME's as peptides/large molecules
Owner Drug MOA Comments
VKTX VK2809 GLP1/GIP Had exceptional tolerability in Ph1 while providing 3.3% weight loss vs placebo. Longer/larger trial may show improved benefits due to long half life.
NVO Amycretin GLP1/Amylin Great topline wt. loss in ph1 but... Not progressing until injectable form data out...very limited data released by NVO…small study. This is a combination of GLP1 and amylin a single drug.
Hercules HRS-9531 GLP1/GIP Hercules is private co formed from 4 JV firms licensing from Jiangsu Hengrui Pharmaceutical. This dual agonist is being trialed in both oral and subq forms. No public data available
Most Interesting NME's small molecules from PUBLIC companies
Owner Drug MOA Comments
LLY Orforglipron GLP1 In ph2 the highest dose of 120mg got 3% weight loss at 4 wks, 8% at 8wks, and 13% at 36 weeks per GSBR comparison presentation
AZN AXD5004 GLP1 2 Phase 2b studies planned (Obese and T2D)- small molecule GLP1- AZN paid 185mill + up to 1.8B milestones + royalties for compound
PFE PF-06954522 GLP1 GLP1 for Type 2 Diabetes - just entered Ph1- very little info
GPCR GSBR-1290 GLP1 In ph2 study only showed 4% weight loss at 8weeks but released updated data to show 6.2% at 12 wks. Still looks inferior to LLY's Orforglipron for both weight loss and T2D (Significant weight loss shown in 28day Phase 1 (up to 4.9%) was not borne out in larger ph2 study) Note that PBO weight loss was as 0% so PBO adjusted and absolute weight loss %’s ar4e the same.
TERN TERN-601 GLP1 Data due 2h24 from phase 1.
PFE Not Named GLP1 Oral in Ph1- mentioned Leerink. M Dolsten said ->The second is another GLP-1 that has some different features also in the clinic and looks encouraging when it comes to PK and dose.
PFE Not Named Non-GLP1 See #msg-173587109. Also- At Leerink M Dlosten said "But it's one of those mechanisms that being validated by biologicals from companies that are in that space,...the type of mechanism that you hear from Lilly and Novo. ... being the first company to make an oral version of it.
Most Interesting NME's small molecules from PRIVATE companies
Empros EMP16 Non GLP1 Avg 8% wt. loss over a year. targeted at maintenance. Uses a combo of two off patent drugs Orlistat and Acarbose.
NodThera NT-0796 NLRP3 Not as effective as a GLP1 for weight loss but may be for those who can't tolerate GLP1 or has cardio issues
Kallyope K757&K833 Hormone new oral nutrient receptor agonists that stimulate the secretion of multiple appetite-suppressing satiety hormones
Hercules HRS-7525 GLP1 In Chinese ph2 trial. Hercules is private co formed from 4 JV firms licensing from Jiangsu Hengrui- very little public data.
Aphaia APHD-012 Hormone Specially coated oral glucose. In Ph2. Private company
Aardvark ARD-101 TAS2R TAS2R agonist that is supposedly activating GLP1 and CCK. This drug originally was for the rare disease market for Prader-Willi syndrome a rare genetic form of obesity see #msg-174141586
May surprise
Owner Drug MOA Comments
PFE PF-06882961 GLP1 Danuglipron- Small Molecule- completed ph1 and in ph2b
NOVO Rybelsus GLP1 Semaglutide- approved for Diabetes only but used off label
GILD GS-4571 GLP1 did preclinical work with obese monkeys that showed some promise.
Not going forward
Owner Drug MOA Comments
PFE Lotiglipron GLP1 Discontinued due to elevated liver enzymes
AMGN AMG736 Undisclosed Dropped pursuit of oral and going full speed ahead with Maritide AMG133 (injectable) instead.
PBMs cause higher drug prices, FTC says:
https://www.wsj.com/health/healthcare/big-pharmacy-benefit-managers-increase-drug-costs-ftc-says-c6a40ee6
The FTC, in a report released Tuesday, detailed a number of actions that it said large pharmacy-benefit managers use to boost their profits and increase the spending of the health plans and employers that hired them to control costs. The actions can also lead to higher outlays for patients at the pharmacy counter, the agency said.
Roche enters_the CGM market—in EU only—(for now):
https://www.globenewswire.com/news-release/2024/07/09/2910036/0/en/Roche-receives-CE-Mark-for-its-AI-enabled-continuous-glucose-monitoring-solution-offering-critical-predictions-to-people-living-with-diabetes.html
This may explain why ABT and DXCM are down 2%-3% this week.
OPT/OPT.AX touts relevance of VEGF-C/VEGF-D pathways_in wAMD:
https://www.globenewswire.com/news-release/2024/07/09/2910252/0/en/Opthea-Announces-Publication-on-VEGF-C-and-D-Signaling-Pathways-as-Potential-Targets-for-Treatment-of-Wet-AMD.html
OPT-302 phase-2b data in wAMD: #msg-150372392. OPT302 is also being tested in DME, as far as I know (#msg-156178510).
AEON repositions ABP-450 as_a potential Botox biosimilar:
https://finance.yahoo.com/news/aeon-biopharma-announces-strategic-reprioritization-120000126.html
AEON is nearly insolvent (#msg-174417740), so it’s hard to see how they complete a phase-3 trial to obtain FDA approval using the 351(k) pathway.
This looks like another instance of Zebra’s Law.
Reminder: ABP-450 is the same drug as EOLS’ Jeuveau, sourced from Korea’s Daewoong.
Thanks, db. Excluding 2008—when a severe bear market lowered valuations enough to generate a 112% average buyout premium—I do not discern a pattern in the data.
It may be that the average buyout premium in a given year is inversely related to the average deal size for that year.
PFE—I did find the CSO haughty on a cc I listened to last year and he was a turn off.
Having survived endolphthalmitis resulting from a leaky glaucoma surgery bleb many years ago with vision intact, I can testify it is not a side effect I care to experience again. Indeed, I keep a bottle of antibiotics in my refrigerator as a prophylactic for situations where I have any reason to believe I might have an eye infection.
If, as you say, patients "substantially preferred" the implant over monthly injections notwithstanding the fact that the insertion is not trivial and the risks described in the package insert WorstLuck linked to are pretty horrifying, that suggests to me that the demand for a longer lasting but safer product is huge.
the Susvimo label
The pros/cons of a refillable implant versus a biodegradable implant for wAMD would seem to be apropos to the threads on OCUL and EYPT.
In the case of EYPT, bioerodible.
If I get a burger from a drive thru - the burger is mostly bioabsorbable through digestion but the packaging, which may be biodegradable, would be hard or impossible to digest.
They may all technically be a form of biodegradable, but when asked to compare a 'canister' to something 'biodegradable' all that comes to mind is a landfill, lol. [eom]
Use bioabsorbable or bioresorbable if you prefer.
No problem (eom).
Dew, hope you don't mind I linked to and used your data(?) https://stocktwits.com/bs010101/message/578825976
Pretty sure biodegradable isn't the term you want.
Wiki:
Biodegradation is the breakdown of organic matter by microorganisms, such as bacteria and fungi.[a][2] It is generally assumed to be a natural process, which differentiates it from composting. Composting is a human-driven process in which biodegradation occurs under a specific set of circumstances.
Addendum—The pros/cons of a refillable implant versus a biodegradable implant for wAMD would seem to be apropos to the threads on OCUL and EYPT.
Thanks. Didn’t think so, but thought I’d ask.
PLSE. Dew a little " blast from the past "....or Duggan strikes again
Pulse Biosciences, Inc. (Nasdaq: PLSE) (the "Company" or "Pulse Biosciences"), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced that it has received the Breakthrough Device Designation from the U.S. FDA for the Company’s Cardiac Surgery System for the ablation of cardiac tissue for the treatment of atrial fibrillation (AF).
Roche’s Susvimo—(6mo Lucentis implant)—back_on_US_market_for_wAMD_following_quality-control_enhancements:
https://www.globenewswire.com/news-release/2024/07/08/2909827/0/en/Roche-to-reintroduce-Susvimo-in-the-US-for-people-with-neovascular-age-related-macular-degeneration-nAMD.html
Susvimo won FDA approval for wet AMD in Oct 2021, but Roche recalled the product one year later due to quality-control issues (https://www.gene.com/download/pdf/Susvimo_DHCP_Important_Prescribing_Information_2022-10-18.pdf ).
Susvimo is refillable, not biodegradable.
HLVX—(-87%)—reports phase-2b failure_of norovirus vaccine in infants:
https://www.globenewswire.com/news-release/2024/07/08/2909536/0/en/HilleVax-Reports-Topline-Data-from-NEST-IN1-Phase-2b-Clinical-Study-of-HIL-214-in-Infants.html
• The NEST-IN1 clinical study did not meet its primary or secondary efficacy endpoints, and the company will discontinue further development of HIL-214 in infants
• The company is exploring the potential for continued development of HIL-214 and HIL-216 in adults
Recent Biotech Buyouts of Publicly Traded Companies
[Added LLY-MORF.]
Table entries are in descending order of buyout premium.
Reverse-mergers are listed at the bottom.
Acquired ‡Premium *Deal iHub
Company Buyer to Market Value Date Reference
LOGC AZN 667% $70M 10/22 #msg-170099482
TBRA AGN 498% $615M 9/16 #msg-125266132
AVRX CLDA 487% $8M 10/08 #msg-33212809
GNLB GSK 465% $57M 10/08 #msg-33209281
AGRX InsudPhrm 336% $45M 6/24 #msg-174661096
DMTX RARE 396% $167M 10/17 #msg-135053781
CMPI REGN 336% $250M 4/22 #msg-168585070
MEMY Roche 319% $50M 11/08 #msg-33787598
IMDZ MRK 311% $300M 2/19 #msg-147004924
SGTX LLY 280% $35M 6/23 #msg-172236626
PRVB SNY 273% $2.9B 3/23 #msg-171430824
KDS.AS SNY 272% $360M 11/20 #msg-159250085
ANDS Roche 256% $220M 10/11 #msg-68043946
SYNB PFE 240% $10M 12/10 #msg-58221573
IDIX MRK 239% $3.85B 6/14 #msg-103051902
KOSN BMY 233% $190M 5/08 #msg-29647147
ZYNE HRMY 226% $60M 8/23 #msg-172590073
MIRO UTHR 213% $91M 10/23 #msg-173118733
TRIL PFE 204% $2.3B 8/21 #msg-165570289
ACER ZVRA 203% $15M 8/23 #msg-172730826
TSRO GSK 182% $5.1B 12/18 #msg-145223384
VLA.AX MRK 182% $394M 2/18 #msg-138708052
SQNM LH 182% $367M 7/16 #msg-124139335
NSPH LMNX 179% $77M 5/16 #msg-122867416
AIMT Nestlé 174% $2.6B 8/20 #msg-157987026
TCXK.PA SGMO 174% $84M 7/18 #msg-142384127
THOR SNY 172% $2.4B 12/19 #msg-152685325
MGRM LH 171% $155M 6/09 #msg-38960958
NEU.ST AMGN 169% $167M 5/19 #msg-148961436
COLY PFE 167% $165M 11/07 #msg-24600805
INHX BMY 163% $2.5B 1/12 #msg-70636307
LABP ABBV 161% $138M 3/24 #msg-174106073
CYPB Ramius 160% $255M 12/10 #msg-57780859
VTAE AGN 159% $639M 9/16 #msg-125144641
NTMD Deerfld z158% z$36M 1/09 #msg-35132470
CELL BRKR 150% $108M 8/23 #msg-172624283
ICGN PFE 150% $56M 7/11 #msg-65365128
EYE ABT 149% $2.8B 1/09 #msg-34762429
IOMI Intercell 147% $190M 5/08 #msg-29232165
DNL.L NBIX 144% $56.5M 8/22 #msg-169825867
STML Menarini 142% $623M 5/20 #msg-155412863
CPEX FCB_Hldgs 142% $77M 3/11 #msg-61326856
SCTL CoreRx 129% $139M 2/24 #msg-173944768
GEVA ALXN 136% $8.4B 5/15 #msg-113395760
BTRX Stiefel 136% $150M 6/08 #msg-30201906
LMNL Strc Alph 135% $10M 7/23 #msg-172324343
PAND MRK 134% $1.85B 2/21 #msg-162128146
ISTA Bausch&Lm 134% $500M 3/12 #msg-73708628
PTLA ALXN 132% $1.2B 5/20 #msg-155434665
SOMX PTX 127% $25M 12/12 #msg-82334111
Tepnel GPRO 126% $132M 1/09 #msg-35221710
INSV Sun_Phrma 125% $48M 9/15 #msg-116997898
ABLX SNY 123% $4.8B 1/18 #msg-138081925
TPTX BMY 122% $4.1B 6/22 #msg-169044829
ONCE Roche 122% $4.3B 2/19 #msg-147078413
CINC AZN 121% $1.3B 1/22 #msg-170897861
CYNA Sunovion 121% $624M 8/16 #msg-124897051
TTHI OPK 121% $60M 6/16 #msg-123621440
ADLR CBST 121% $190M 10/11 #msg-68264754
SGXP LLY 119% $64M 7/08 #msg-30547648
MDVN PFE k118% $4.0B 8/16 #msg-124680992
HARP MRK 118% $680M 1/24 #msg-173581189
ENCY PFE 118% $350M 2/08 #msg-26978155
CCXI AMGN 116% $3.7B 8/22 #msg-169584273
RARX UCB.BR 112% $2.1B 10/19 #msg-151624039
OPNT INDV.L 111% $110M 11/22 #msg-170443638
HZD.L PKI 110% $368M 11/20 #msg-159255066
BOLD ALPMY 110% $3.0B 12/19 #msg-152574418
IMMU GILD 108% $21B 9/20 #msg-158261866
ICEL Fujifilm 108% $307M 3/15 #msg-112226224
AMYT Chiesi 107% $1.25B 1/23 #msg-170892902
IMGO MRK 107% $1.4B 11/22 #msg-170504136
ARQL MRK 107% $2.7B 12/19 #msg-152684415
AMAM JNJ 105% $2.0B 1/24 #msg-173581189
RYZB BMY 105% $3.6B 12/23 #msg-173501393
TRCA IPN.PA 104% $660M 6/08 #msg-29795183
BLU GSK 103% $2.0B 4/23 #msg-171710496
GBT PFE 102% $5.4B 8/22 #msg-169612752
MRV.TO Srchlight 101% $91M 12/22
AMLN BMY 101% u$7.0B 6/12 #msg-77122453
ARNA PFE 100% $6.7B 12/21 #msg-167099213
TST.TO PLI.TO 100% $33M 8/16 #msg-124735566
HGSI GSK 99% $3.0B 7/12 #msg-77532608
FUSN AZN 97% $2.1B 3/24 #msg-174067117
ORTX KYKOY 97% $387M 19/23 #msg-172963268
CRY.TO MDT 97% $380M 9/08 #msg-32421462
CFMS restor3D 96% $18M 6/23 #msg-172198000
UROV Sumitovant 96% $681M 11/20 #msg-159462428
FTSV GILD 96% $4.9B 3/20 #msg-154105690
NVDQ SYK 96% $701M 6/17 #msg-132304937
IMGN ABBV 95% $10B 11/23 #msg-173325886
CHMA AMYT 94% $330M 5/21 #msg-163605477
BITI ACOR 94% $363M 1/16 #msg-119923883
Speedel NVS 94% $880M 7/08 #msg-30588524
HTWR MDT 93% $1.1B 6/16 #msg-123551339
MEDA.ST MYL 92% $9.9B 2/16 #msg-120456111
MNT JNJ 92% $1.1B 11/08 #msg-33879830
JUNO CELG j91% $9.0B 1/18 #msg-137859642
OCAT Astellas 91% $379M 11/15 #msg-118374922
GI BSX 90% $210M 9/16 #msg-125422608
MEDX BMY 90% $2.1B 7/09 #msg-39801273
CTIC SOBI.ST 89% $1.7B 5/23 #msg-171878780
VRUS GILD 89% $11B 11/11 #msg-69211700
AVXS NVS 88% $8.7B 4/18 #msg-139888382
AGN ACT q88% $66B 11/14 #msg-108238424
OMTH AZN 88% $260M 5/13 #msg-88349427
PNT LLY 87% $1.4B 10/23 #msg-172949338
MAKO SYK 86% $1.65B 9/13 #msg-92358712
ISO BLI 85% $58M 12/22 #msg-170759670
SIRT GSK 85% $620M 4/08 #msg-28705020
ALBO IPN.PA 84% $950M 1/22 #msg-170897349
LJPC INVA 84% $148M 7/22 #msg-169366685
ALDR LUND.CO 84% $1.95B 9/19 #msg-151154641
ZGEN BMY 84% $885M 9/10 #msg-54152162
AMBI Daiichi 83% $315M 9/14 #msg-106688411
ICPT Alfasigma 82% $870M 9/23 #msg-172898719
TRIV ELGX 81% $211M 10/15 #msg-118008485
YMI GILD 81% $510M 12/12 #msg-82377008
NGM Column Gp 80% $135M 2/24 #msg-173922864
DRNA NVO 80% $3.3B 11/21 #msg-166818260
PRVL LLY 80% $880M 12/20 #msg-160184274
TIG TAK 80% $622M 1/18 #msg-137517859
MORF LLY 79% $3.2B 7/24 #msg-174719164
FSTX Sino BPhrm 79% $161M 6/22 #msg-169222236
BHVN PFE 79% $11.6B 5/22 #msg-168806558
KDMN SNY 79% $1.9B 9/21 #msg-165815381
FPRX AMGN 79% $1.9B 3/21 #msg-162316864
CVRS SHL.DE 79% $1.1B 8/19 #msg-151997721
CASC SGEN 79% $614M 1/18 #msg-138145273
AKUS LLY 78% $497M 10/22 #msg-170225029
NTGN BNTX 77% $67M 1/20 #msg-153334198
ACHN ALXN 77% $700M 10/19 #msg-151730899
ATLN.VX JNJ f77% $30B 1/17 #msg-128155201
ORIDN.SW COV 77% $300M 4/12 #msg-74079493
ADMS SUPN 76% $400M 10/21 #msg-166306594
CVTX GILD 76% $1.4B 3/09 #msg-36225695
ALIM ANIP 75% $381M 6/24 #msg-174649330
DCPH Ono Pharma 75% $2.4B 4/24 #msg-174321509
RXDX MRK 75% $10.8B 4/23 #msg-171696785
ARIA TAK 75% $5.2B 1/17 #msg-127718101
CALT AsahiKasei 74% $1.1B 5/24 #msg-174499469
OLK TMO 74% $3.1B 10/23 #msg-173043188
RXDX Roche 74% $1.7B 12/17 #msg-137115144
MOVET.BR SHPG 74% $560M 8/10 #msg-52918245
IDEV ENDP 74% $370M 1/09 #msg-34592416
CERE ABBV f73% $8.7B 12/23 #msg-173374544
CPXX JAZZ 73% $1.5B 5/16 #msg-122995888
LEVP VPHM y73% y$510M 7/08 #msg-30704409
TARG MDCO 72% $42M 1/09 #msg-34774402
Ventana Roche 72% $3.4B 1/08 #msg-30912677
Jerini SHPG 71% $520M 7/08 #msg-30452872
MNTA JNJ 70% $6.5B 8/20 #msg-157719675
WTX.ST ALXN 70% $855M 4/18 #msg-139951584
APNO Cell_Bio 70% $20M 9/09 #msg-43348606
TCRR ADAP 69% $80M 3/23 #msg-171370279
AAH.AX CEPH 69% $207M 2/09 #msg-35956544
JNCE Tang Cptl 68% $99M 3/23 #msg-171548303
CNST MOR 68% $1.7B 6/21 #msg-164153449
NITE BIIB 68% $877M 3/19 #msg-147257363
LOXO LLY 68% $8.0B 1/19 #msg-145917745
ARMO LLY 68% $1.6B 5/18 #msg-140678701
STDY UTHR 68% $216M 4/18 #msg-140410572
DDS.TO PLB.TO 68% $15M 8/11 #msg-66272770
ALPN VRTX 67% $4.9B 4/24 #msg-174214641
KDNY NVS 67% $3.2B 6/23 #msg-172110415
APEN BSX 67% $615M 11/22 #msg-170560661
CMTA IPN.PA 67% $1.31B 2/19 #msg-147078420
ALXA Gp_Ferrer 67% $20M 5/16 #msg-122522140
ZGNX UCB.BR 66% $1.9B 1/22 #msg-167551981
NVET ZTS 66% $85M 4/17 #msg-130461127
DRTX ACT 66% $675M 10/14 #msg-106925472
SPPI ASRT 65% $250M 4/23 #msg-171766836
LPDX LH 65% $83M 9/14 #msg-106598786
OSTE MDT 65% $123M 8/10 #msg-53410183
MDCO NVS 64% $9.0B 11/19 #msg-152458295
FCSC Castle_Crk 64% $63M 9/19 #msg-151108594
BIVV SNY 64% $11.6B 1/18 #msg-137861926
LDRH ZBH 64% $1.0B 6/17 #msg-133419822
TLCR GRFS 64% $3.4B 6/10 #msg-50961841
FACT ABT 64% $450M 3/10 #msg-47606240
Acambis SNY 64% $550M 7/08 #msg-30990498
JAV HSP 64% $141M 4/10 #msg-48881292
MSLI Norgine_BV 63% $249M 5/17 #msg-131262204
GRCL AZN 62% $1.0B 12/23 #msg-173501426
ARRY PFE 62% $11.4B 6/19 #msg-149423883
CBMX NVTA 62% $33M 7/17 #msg-133447160
MOR NVS 61% $2.9B 2/24 #msg-173780339
MYOK BMY 61% $13B 10/20 #msg-158699874
Synthes JNJ 61% $21.5B 4/11 #msg-62473819
SCRX Shionogi 61% $1.4B 9/08 #msg-31859174
APGN PYXS 60% $16M 5/23 #msg-171981599
SHPG TAK 60% $62.1B 5/18 #msg-140610505
XNPT Arbor_Phrm 60% $487M 5/16 #msg-122847495
BRLI OPK 60% $1.5B 6/15 #msg-114296569
MAPP AGN 60% $958M 1/13 #msg-83696395
BFRM Merz 60% $253M 1/10 #msg-45071380
RETA BIIB 39% $7.3B 7/23 #msg-172456806
RLYP Galenica 59% $1.53B 7/16 #msg-124014245
CXS.AX CEPH 59% $163M 3/11 #msg-61453144
CRXL JNJ 58% $2.4B 12/10 #msg-55228522
PFNX LGND 57% $438M 8/20 #msg-157515236
VOLC PHG 57% $1.0B 12/14 #msg-109142343
MEDS XON 57% $26M 12/13 #msg-95175483
AVDR GKOS 56% $480M 8/19 #msg-150387068
OMPI VRX 56% $360M 3/13 #msg-86381607
BMTI WMGI 56% $380M 12/12 #msg-81626598
MTXX HIG_Captl 56% $75M 12/10 #msg-57778844
ASPM COV 56% $210M 9/09 #msg-43348479
ANAC PFE 55% $5.2B 5/16 #msg-122659881
RNA BMRN 55% $840M 11/14 #msg-108456369
AUXL ENDP 55% $2.6B 10/14 #msg-107031514
OSIP Astellas 55% $4.0B 5/10 #msg-50234451
IDMI TAK 55% $75M 5/09 #msg-37898204
COLL BDSI 54% $604M 2/22 #msg-167875055
VEC.L PM 54% $1.5B 8/21 #msg-165430280
CELG BMY 54% $74B 1/19 #msg-145844551
ECYT NVS 54% $2.1B 10/18 #msg-144295734
CPHD DHR 54% $4.0B 9/16 #msg-124976329
GNOM BGI-Shnzhn 54% $118M 9/12 #msg-79636464
RDEA AZN 54% $1.3B 4/12 #msg-74706626
BSMD MMSI 54% $96M 5/10 #msg-50161877
ATSI MDT 54% $370M 4/10 #msg-49617936
ALO KG 54% $1.6B 11/08 #msg-33763449
ABGX AMGN 54% $2.2B 12/05 #msg-8876857
KRTX BMY 53% $14B 12/23 #msg-173484423
EPZM IPN.PA 53% $247M 6/22 #msg-169252695
VIE HZNP 53% $2.67B 2/21 #msg-161376573
MEDI AZN 53% $15.2B 4/07 #msg-19020387
MLNM TAK 53% $8.8B 4/08 #msg-28365383
AMRI Crlyl/GTCR 52% $922M 6/17 #msg-131937504
AFFX TMO 52% $1.3B 1/16 #msg-119712743
TRBN EBS 52% $97M 8/10 #msg-53271836
SYNO BAX 52% $260M 12/11 #msg-69906294
PCOP LGND 52% $75M 9/08 #msg-32404474
FRLN SYNC.L 51% $28M 11/23 #msg-173279258
ABMD JNJ 51% $17B 11/22 #msg-170339688
VIFN.SW CSL.AX 51% $12B 12/21 #msg-167114255
RPBIF OrbiMed 51% $11.1M 6/16 #msg-126868605
NPSP SHPG 51% $5.2B 1/15 #msg-109811213
CLZR ELOS 51% $65M 9/09 #msg-41293512
OMRI JNJ 51% $465M 11/08 #msg-33762745
IMCL LLY 51% $6.5B 10/08 #msg-32662830
QSAM TLX.AX 50% $33M 2/24 #msg-173807713
CSII ABT 50% $890M 2/23 #msg-171160898
MYOV Sumitomo 50% $2.9B 10/22 #msg-170268877
ETTX INVA 50% $113M 5/22 #msg-168944440
ATRS HALO 50% $960M 4/22 #msg-168533921
ITMR Zoll Mdcl 50% $538M 9/21 #msg-165885593
GWPH JAZZ 50% $6.7B 2/21 #msg-161448011
CORI Gurnet_Pnt 50% $504M 10/18 #msg-144156114
ENTL SYK 50% $662M 12/17 #msg-136714935
PSTX SYK 50% $120M 1/14 #msg-95510779
MYOG GILD 50% $2.5B 10/06 #msg-13712121
MIL Merck_KGaA 50% $7.2B 3/10 #msg-47249493
CRGN CLDX 50% $40M 5/09 #msg-38262967
TNOX DNA 50% $919M 11/06 #msg-14673162
FMTX NVO 49% $1.1B 9/22 #msg-169846707
OCRX MNK 49% $75M 11/17 #msg-135889221
HZNP AMGN 48% $28B 12/22 #msg-170671017
WMGI SYK 48% $5.4B 11/19 #msg-152075660
SURG VRX 48% $166M 9/15 #msg-116690920
ZY DNA 47% $300M 7/22 #msg-169486788
AAAP NVS 47% $3.9B 10/17 #msg-168310103
FLXN PCRX 47% $428M 10/21 #msg-166306397
CBM Permira 47% $2.4B 8/19 #msg-150386649
KIN ELAN 46% $440M 6/21 #msg-164417443
AMAG Covis_Grp 46% $647M 10/20 #msg-158641344
BEC DHR 46% $6.8B 2/11 #msg-59624646
PHRM CELG 46% $2.9B 11/07 #msg-24645394
ALXN AZN 45% $39B 12/20 #msg-160128002
AGN ABBV 45% $65B 6/19 #msg-149577810
ROCM BCR 45% $262M 9/13 #msg-91684202
TYME SYRS 44% $70M 7/22 #msg-169317107
BSTC ENDP 44% $540M 10/20 #msg-158976969
AAAP NVS 44% $3.9B 10/17 #msg-135797034
GNVC XON 44% $14.2M 1/17 #msg-128087921
ICVX AZN 43% $800M 12/23 #msg-173410902
DBTX REGN 43% $109M 8/23 #msg-172552134
VECT IRWD 43% $1.0B 5/23 #msg-171960647
AVEO LG Chem 43% $566M 10/22 #msg-170225142
GNMK Roche 43% $1.8B 3/21 #msg-162557955
SNMX Firmenich 43% $72M 9/18 #msg-143614780
RPRX AGN 43% $27M 12/17 #msg-136820335
DICE LLY 42% $2.4B 6/23 #msg-172170829
SGEN PFE 42% $43B 3/23 #msg-171430587
AGTC SYNC.L 42% $24M 10/22 #msg-170272356
ZSPH AZN 42% $2.7B 11/15 #msg-118292261
ASPX TEVA 42% $3.2B 3/15 #msg-112224762
CALP PKI 42% $600M 9/11 #msg-66915400
BRL TEVA 42% $9.0B 7/08 #msg-30792830
PRTK Gurnet Pt 41% $330M 6/23 #msg-172070130
EIDX BBIO 41% $2.9B 10/20 #msg-158699182
AST BTX 41% $85M 11/18 #msg-144764100
VITA SYK 41% $320M 5/11 #msg-63178312
AGAM STJ 41% $1.3B 10/10 #msg-55673504
MNLO FOMX 40% $180M 11/19 #msg-152208625
DSCI IART 40% $204M 1/17 #msg-127779613
SGNT Nichi-Iko 40% $736M 7/16 #msg-123792475
PATH TEVA 40% s$144M 1/14 #msg-96147237
SLTM VRX 40% $236M 12/13 #msg-95003986
KG PFE 40% $3.6B 10/10 #msg-55425514
STSA Shin Nippn 39% $30M 4/23 #msg-171700091
SRRA GSK 39% $1.9B 4/22 #msg-168533694
PCYC ABBV n39% $21B 3/15 #msg-111425234
SYR.L STE 39% $1.9B 10/14 #msg-107152734
HSP PFE 39% $17B 2/15 #msg-110577169
MRX VRX 39% $2.6B 9/12 #msg-79186818
CEPH TEVA 39% $6.8B 5/11 #msg-62636692
ORCH LH 39% $85M 4/11 #msg-61801828
MOGN Eisai 39% $3.9B 12/07 #msg-25163775
SPNE OFIX 38% $306M 10/22 #msg-170165454
PETX ELAN 38% $231M 4/17 #msg-148466146
ALR ABT 38% $7.9B 4/17 #msg-130492505
BXLT SHPG 38% $32B 1/16 #msg-119743932
ITMN Roche 38% $8.3B 8/14 #msg-105603127
SNTS SLXP 38% $2.6B 11/13 #msg-93839578
ONXX AMGN 38% $9.7B 8/13 #msg-91383118
LIFE TMO 38% $15.6B 4/13 #msg-86836458
DUSA Sun_Pharma 38% $230M 11/12 #msg-81273572
AERI ALC 37% $770M 8/22 #msg-169759599
TTPH LJPC 37% $43M 6/20 #msg-156488296
BTG.L BSX 37% $4.2B 11/18 #msg-145001575
STJ ABT 37% $30.7B 4/16 #msg-122251293
CBST MRK 37% $9.5B 12/14 #msg-108853418
SIAL Merck_KGaA 37% $17B 9/14 #msg-106484466
PRX TPG_(prvt) 37% $1.9B 7/12 #msg-77533202
MTOX LH 37% $240M 6/12 #msg-76240732
GENZ SNY v37% v$20.1B 2/11 #msg-59975091
DOVA SOBI.ST 36% $810M 9/19 #msg-151425501
MRTX BMY 35% $4.8B 10/23 #msg-172983547
SURF CHRS 35% $40M 6/23 #msg-172154287
SOBI.ST Advent/GIC 35% $8.0B 9/21 #msg-165744197
CORV Advance_Ph 35% $76M 3/20 #msg-154356839
PTHN TMO 35% $7.2B 5/17 #msg-131355584
DYAX SHPG 35% $5.9B 11/15 #msg-118164544
MATK Royal_DSM 35% $1.1B 12/10 #msg-57987049
MITO Mrngsd Vnt 34% $27M 8/22 #msg-169552098
NEOS AYTU 34% $45M 12/20 #msg-160066262
WCRX ACT 34% $8.5B 5/13 #msg-88088454
AMMD ENDP 34% $2.9B 4/11 #msg-61948007
CLRT GE 34% $580M 10/10 #msg-55864640
SGP MRK 34% $41B 3/09 #msg-36140327
HTRN ENDP 34% $223M 5/10 #msg-49838813
CLCD LLY 33% $960M 1/17 #msg-127941157
AKGZF Bayer 33% $2.9B 12/13 #msg-95174198
KNSY Royal_DSM 33% $360M 5/12 #msg-75204020
MITI AMGN 33% $1.16B 1/12 #msg-71341339
OYST VTRS 32% $300M 11/22 #msg-170389075
JNP CTLT 32% $140M 7/18 #msg-141961886
CVD LH 32% $5.6B 11/14 #msg-107784169
SMTS COV 32% $250M 6/10 #msg-51344183
EXAC TPG_(prvt) 31% $625M 10/17 #msg-135627315
TOMO ARAY 31% $277M 3/11 #msg-60697854
TBIO SNY 30% $3.2B 8/21 #msg-165242244
PRAH ICLR 30% $12B 2/21 #msg-162100993
NXTM FMS 30% $2.0B 8/17 #msg-133627112
THOR STJ 30% $3.4B 7/15 #msg-115599422
PPD(I) CarlyleGrp 30% $3.9B 10/11 #msg-67625255
OctoPlus RDY 30% $35M 10/12 #msg-80752228
CGPI Galderma 30% $420M 2/08 #msg-28286522
NTUS ArchiMed 29% $1.2B 4/22 #msg-168574161
XLRN MRK 29% $11.5B 9/21 #msg-166156870
IVTY SYK 29% $190M 9/18 #msg-143493139
FMI Roche 29% h$2.4B 6/18 #msg-141630144
COV MDT 29% $42.9B 6/14 #msg-103352775
CHTP Lundbeck 29% $530M 5/14 #msg-101687352
WYE PFE 29% $68B 1/09 #msg-35077617
APPX Fresenius 29% $940M 7/08 #msg-30498388
KITE GILD 29% $11.9B 8/17 #msg-134179317
GTKX.PA CALT 28% $38M 8/20 #msg-157592686
PRXL Pamplona 28% $4.6B 6/17 #msg-132330332
INNL Gurnet_Pt 28% $53M 4/17 #msg-130210863
CYNO HOLX 28% $1.44B 2/17 #msg-128697104
CRA DGX 28% $330M 3/11 #msg-61103240
SEPR Dainippon 28% $2.6B 9/09 #msg-41143301
CBAY GILD 27% $4.3B 2.24 #msg-173827237
NVCN SWAV 27% $199M 1/23 #msg-170962426
OXFD PKI 27% $600M 1/21 #msg-160749373
HEMA CRL 27% $380M 12/19 #msg-152826703
SPNC PHG 27% $2.16B 6/17 #msg-132563070
QCOR MNK 27% $5.6B 4/14 #msg-100144844
CNJ.TO EBS 27% $222M 12/13 #msg-94886880
GIVN COV 27% $860M 12/13 #msg-94759019
VPHM SHPG 27% $4.2B 11/13 #msg-93924184
ASTX Otsuka 27% $886M 9/13 #msg-91706292
ALTH SPPI 27% $108M 4/12 #msg-74081029
GXDX NVS 27% $330M 1/11 #msg-59092015
SOLY ABBV 26% $550M 5/21 #msg-163706786
KTWO SYK 26% $1.4B 8/18 #msg-143281972
LBMH BCR 26% $181M 11/15 #msg-118658269
CFN BD 26% $12.2B 10/14 #msg-106924866
CADX MNK 26% $1.3B 2/14 #msg-97103062
ISPH MRK 26% $430M 4/11 #msg-61724403
Zentiva SNY 26% $2.6B 9/08 #msg-32327005
AMTI CYTH 25% $11M 12/23 #msg-173513038
CEMI ALBIO.PA 25% $17.2M 1/23 #msg-171085285
KARO.ST EQT_VIII 25% $650M 10/18 #msg-144517455
BCR BDX 25% $24B 4/17 #msg-130730335
SLXP VRX p25% $15.9B 3/15 #msg-111768607
FRX ACT 25% $25B 2/14 #msg-97422529
ICOS LLY 25% $2.3B 12/06 #msg-15623908
PPD TMO 24% $20.9B 4/21 #msg-163201848
VAR SHL.DE 24% $16.4B 8/20 #msg-157315433
KYTH AGN 24% $2.1B 6/15 #msg-114667193
HITK AKRX 24% $540M 8/13 #msg-91428592
ZOLL AsahiKasei 24% $2.2B 3/12 #msg-73194976
RCOR RCKT 23% $53M 9/22 #msg-169991990
LMNX DIA.MI 23% $1.8B 4/21 #msg-163126009
ISEE Astellas 22% $5.9B 5/23 #msg-171807035
ALMED.PA MDT 22% $160M 7/20 #msg-156929697
Noven Hisamitsu 22% $428M 7/09 #msg-39515681
RPTP HZNP 21% $800M 9/16 #msg-125097197
DNEX TMO 21% $2.1B 12/10 #msg-57686719
EQRX RVMD 20% $1.1B 8/23 #msg-172491486
PLB.TO ENDP 20% $74M 11/13 #msg-93718507
CPTS Bayer 20% $1.1B 4/13 #msg-87353545
PBTH OPK 20% $480M 4/13 #msg-87185863
GPRO HOLX 20% $3.7B 4/12 #msg-74999864
FURX FRX 19% $1.1B 4/14 #msg-101191792
CLDA FRX 19% $1.2B 2/11 #msg-60171753
PPCO ENDP 19% $168M 8/10 #msg-53137069
EVVV COV 19% $2.6B 6/10 #msg-50797343
RCPT CELG 18% $7.2B 7/15 #msg-115406201
SWAV JNJ 17% $12.5B 4/24 #msg-174182514
CTLT NVO Hldngs 17% $11.5B 2/24 #msg-173773953
RAIN Pathos AI 17% c.v. 12/23 #msg-173423820
PRDS MediPac 17% c.v. 7/23 #msg-172362079
MSON BVS 17% $518M 7/21 #msg-166521465
BEAT PHG 17% $2.8B 12/20 #msg-160299656
NDRM Mitsubishi 17% $1.1B 7/17 #msg-133239153
KCI Apax_Prts 17% $6.3B 7/11 #msg-65162696
ABII CELG 17% $2.9B 6/10 #msg-51844360
ACL NVS x17% x$49.7B 1/10 #msg-45072999
CNCE Sun Pharma 16% $580M 1/23 #msg-170981214
MZOR MDT 16% $1.64B 9/18 #msg-143696059
VER.L LGND 16% $43M 8/18 #msg-142795933
ABAX ZTS 16% $2.0B 5/18 #msg-140837816
AEGR QLTI m16% $45M 6/16 #msg-123312384
KMNS XIO_Grp 16% $510M 6/15 #msg-114711266
PRXN.L Upshr-Smth 16% $350M 6/12 #msg-76556065
CGRB JNJ 16% $970M 5/09 #msg-38039851
DNA Roche 16% w$46.8B 3/09 #msg-36224175
XENT MDT 15% $1.1B 8/21 #msg-165323285
SCMP MNK 15% $1.2B 12/17 #msg-137177653
TSRX CBST 15% $707M 7/13 #msg-90492857
ARI.TO Roche 15% $190M 7/08 #msg-30904056
EMIS NVO 14% $1.8B 11/20 #msg-159336565
ZLTQ AGN 14% $2.48B 2/17 #msg-128649430
FEIC TMO 14% $4.2B 5/16 #msg-122953139
SENO BCR 14% $213M 5/10 #msg-49838776
SBBP XERS 13% $267M 5/21 #msg-163992064
PGNX LNTH 13% $440M 2/20 #msg-153933488
AVNR Otsuka 13% $3.5B 12/14 #msg-108677894
RDUS Gurnet Pt 12% $890M 6/22 #msg-169222128
SCLN GL_Capital 11% $605M 6/17 #msg-132004673
WX prvt_grp 11% $3.3B 8/15 #msg-116208102
ELN PRGO 11% $6.7B 7/13 #msg-90418077
PRNB SNY 10% $3.36B 8/20 #msg-157669162
TGX Juniper 9% $52M 8/13 #msg-90677660
EURX Axcan 9% $583M 12/10 #msg-57543845
KNTE XOMA 8% $120M 2/24 #msg-173861156
HPTX HZNP 8% $1.1B 3/15 #msg-112225598
PMTI CYNO 8% $294M 3/13 #msg-85810217
TWTI HOLX 7% $580M 6/08 #msg-29877950
ARTC SN.L 6% $1.7B 2/14 #msg-96750072
CEGE BPAX 6% $38M 6/09 #msg-39163410
MEND JNJ 6% $480M 7/10 #msg-52176337
THRX Tang Cptl 5% c.v. 12/23 #msg-173484642
GHDX EXAS 5% $2.8B 7/19 #msg-150192700
ELOS Apax_Prtns 4% $397M 4/17 #msg-130128751
PRON.OL BASF 4% $844M 12/12 #msg-81711876
ABCM DHR 3% $5.7B 8/23 #msg-172703284
DERM LLY 2% $1.1B 1/20 #msg-153222680
GENT JAZZ 2% $1.0B 12/13 #msg-95143526
OSIR SNN 1% $660M 3/19 #msg-147467838
RLM EPIX (3%) $22M 5/19 #msg-148855792
CRTX Chiesi (3%) t$106M 9/13 #msg-92046498
VXGN OXGN (4%) $33M 10/09 #msg-42578130
AVGN MNOV (7%) $38M 8/09 #msg-40769841
VRX BVF (7%) $3.9B 6/10 #msg-51505172
VELO.CO Asahi (9%) $1.3B 11/19 #msg-153256195
GNMX CERC (11%) $16M 12/19 #msg-152639293
KERX AKBA (13%) $475M 6/18 #msg-141859230
OPTR CBST (19%) $535M 7/13 #msg-90492857
ACPH.BR EGRX (30%) $104M 3/22 #msg-168352276
DPLO UNH (31%) $300M 12/19 #msg-152689666
MRLB SIEN (78%) $20M 6/17 #msg-132114929
TLON SPPI ‡(85%) ‡$11M 7/13 #msg-90020541
RPHM OKUR ® ® 5/24 #msg-174406669
KTRA HURA ® ® 4/24 #msg-174166810
ABIO ORCA ® ® 4/24 #msg-174165127
ONTX TRAW ® ® 4/24 #msg-174158771
FWBI ENTO ® ® 3/24 #msg-174432766
AVRO TECX ® ® 1/24 #msg-173735605
FIXX QTTB ® ® 11/13 #msg-173237730
GRPH LENZ ® ® 11/23 #msg-173227879
SELB RNAC ® ® 11/23 #msg-173210464
INVO NAYA ® ® 10/23 #msg-173075987
ADXS Biosight ® ® 7/23 #msg-172456806
NLTX NGNE ® ® 7/23 #msg-172374206
FREQ KRRO ® ® 7/23 #msg-172338919
TALS TRML ® ® 6/23 #msg-172187751
IMNM Morphimmune ® ® 6/23 #msg-172242569
NANOV.OL Thor Med ® ® 6/23 #msg-172098515
MGTA DNTH ® ® 5/23 #msg-171829261
DFFN CRVO ® ® 3/23 #msg-171578139
ADMP DMK Pharma ® ® 2/23 #msg-171314445
VBLT NTBL ® ® 2/23 #msg-171281477
ANGN ELTX ® ® 1/23 #msg-170962134
VLON GRI ® ® 12/22 #msg-170687186
GRAY CALC ® ® 11/22 #msg-170512654
ADXS Ayala ®g ® 10/22 #msg-170233693
IMRA ELVN ® ® 10/22 #msg-170192000
RMED VTAK ® ® 9/22 #msg-170581567
SESN CARM ® ® 9/22 #msg-170005327
GMTX IRON ® ® 8/22 #msg-169638662
SBTX SPRY ® ® 7/22 #msg-169465202
YMTX KA ® ® 6/22 #msg-169066703
CLBS LSTA ® ® 4/22 #msg-168674675
EYES VANI ® ® 2/22 #msg-167798986
POLN.SW SPEX.SW ® ® 12/21 #msg-167295474
AZRX FWBI ® ® 9/21 #msg-165885811
EARS CYTO ® ® 6/21 #msg-164184643
ARPO AADI ® ® 5/21 #msg-163841604
MLND TPST ® ® 3/21 #msg-162851398
APOP Quoin_Phrm ® ® 3/21 #msg-162798374
NTEC INDP ® ® 3/21 #msg-162565942
OBLN RSLS ® ® 1/21 #msg-161068114
NK IBRX ® ® 12/20 #msg-160358069
SNCA PALI ® ® 12/20 #msg-160265342
ANCN CMMB ® ® 12/20 #msg-160187408
SNSS VIRX ® ® 11/20 #msg-159786611
AKER MYMD ® ® 11/20 #msg-159445834
CBLI STAB ® ® 10/20 #msg-158993566
PTI YMTX ® ® 8/20 #msg-157833849
CGIX VYNT ® ® 8/20 #msg-157834952
ARYBU CERE ® ® 7/20 #msg-157265361
SBPH FSTX ® ® 7/20 #msg-157245800
UMRX Kiq_LLC ® ® 7/20 #msg-156717827
REXN OCUP ® ® 6/20 #msg-156362145
ADRO KDNY ® ® 6/20 #msg-155991705
NTRP PTPI ® ® 5/20 #msg-155701445
TORC ACET ® ® 4/20 #msg-155341382
ARYA IMTX ® ® 3/20 #msg-155937184
TOCA FBRX ® ® 2/20 #msg-153935298
BPMX TMBR ® ® 1/20 #msg-153535078
CNAT HSTO ® ® 1/20 #msg-153532517
RTTR QLGN ® ® 1/20 #msg-153405835
ZFGN LRMR ® ® 12/19 #msg-152862497
NLNK LUMP ® ® 9/19 #msg-151442042
PRTO TARA ® ® 9/19 #msg-151308631
OPGN CURE.AS ® ® 9/19 #msg-150924660
AQXP NLTX ® ® 8/19 #msg-150347293
GEMP NRBO ® ® 7/19 #msg-150120289
MYND EMMA ® ® 7/19 #msg-150069355
CHAC PHGE ® ® 7/19 #msg-150003368
VICL BBI ® ® 6/19 #msg-149171531
ALQA ADYX ® ® 4/19 #msg-148356921
MATN OTLC ® ® 4/19 #msg-148312861
HSGX OCGN ® ® 4/19 #msg-148102776
VTL IMUX ® ® 4/19 #msg-148027472
SBOT EDSA ® ® 3/19 #msg-147384278
GTXI ONCT ® ® 3/19 #msg-147349916
FLKS SLRX ® ® 1/19 #msg-145871960
APHB ARMP ® ® 1/19 #msg-145870884
OHRP NBSE ® ® 1/19 #msg-145848413
OMED MREO ® ® 12/18 #msg-145273044
ASNS XFOR ® ® 11/18 #msg-145105702
EDGE PDSB ® ® 11/18 #msg-145087200
ORPN ENLV ® ® 11/18 #msg-144993741
OVAS MLND ® ® 8/18 #msg-142796422
APRI SEEL ® ® 7/18 #msg-142554689
TPIV MRKR ® ® 6/18 #msg-141234250
VSAR ARAV ® ® 6/18 #msg-141288246
PSDV EYPT ® ® 4/18 #msg-139636450
DDRT ENOB ® ® 2/18 #msg-155616042
SVON ELOX ® ® 12/17 #msg-137129259
AVIR VXRT ® ® 10/17 #msg-135798068
NEOT EVFM ® ® 10/17 #msg-135475699
IPXL AMRX ® ® 10/17 #msg-135476435
HUWX PCSA ® ® 10/17 #msg-135169711
ADHD ARCT ® ® 9/17 #msg-134959115
ITEK RCKT ® ® 9/17 #msg-134563146
OXIS GTBP ® ® 8/17 #msg-133992461
CEMP MLNT ® ® 8/17 #msg-133699889
GALE SLS ® ® 8/17 #msg-133668985
AEPP ONCX ® ® 8/17 #msg-133655781
MDSI INNT ® ® 7/17 #msg-138124228
OPXA ACER ® ® 7/17 #msg-132682989
MIRN SYBX ® ® 5/17 #msg-131394212
NVLS ALPN ® ® 4/17 #msg-130583796
CERU DARE ® ® 3/17 #msg-129681349
THLD MTEM ® ® 3/17 #msg-129612892
JAGX Napo_Pharma ® ® 2/17 #msg-133472369
PIP ALT ® ® 1/17 #msg-127979048
MSTX SVRA ® ® 1/17 #msg-127699319
OGXI ACHV ® ® 1/17 #msg-127671152
GTCL.PA GKTX.PA ® ® 12/16 #msg-127378262
DPRX PLXP ® ® 12/16 #msg-127377082
TKAI OTIC ® ® 12/16 #msg-127360808
COOL PTE ® ® 12/16 #msg-127170327
MRNA IthenaPhrma ® ® 11/16 #msg-126593922
SGNL MGEN ® ® 11/16 #msg-126214730
TBIO PRPO ® ® 10/16 #msg-125767889
EBIO Viventia ® ® 9/16 #msg-125325110
LPTN APEN ® ® 9/16 #msg-125044826
MCUR LPTX ® ® 8/16 #msg-124830007
STEM MBOT ® ® 8/16 #msg-124542946
CBYL KALV ® ® 6/16 #msg-123315137
AAVL Annapurna ® ® 5/16 #msg-122582472
BIOD ALBO ® ® 5/16 #msg-122880969
SNTA MDGL ® ® 4/16 #msg-121919321
APPY Strand_LS ® ® 1/16 #msg-120095130
RESX DFFN ® ® 1/16 #msg-119714298
CLDN EIGR ® ® 11/15 #msg-118623913
VBI SVACF ® ® 10/15 #msg-120043416
CLTX Volution ® ® 7/15 #msg-115354702
RTGN PULM ® ® 6/15 #msg-114559267
TBUFF POZN ® ® 6/15 #msg-114404029
DARA MTPH.L ® ® 6/15 #msg-114299115
TRGT CBIO ® ® 3/15 #msg-111461780
RGDO TBRA ® ® 1/15 #msg-109912303
TKMR ABUS ® ® 1/15 #msg-109820030
TSPT PRTK ® ® 7/14 #msg-103895855
VTUS ASMB ® ® 5/14 PR link
TELK MBVX ® ® 5/14 #msg-101987443
ZLCS EPRS ® ® 4/14 #msg-100707725
NABI Biota ® ® 11/12 #msg-81312718
TRMS GEVA ® ® 6/11 #msg-64249161
VSGN IPC ® ® 8/09 #msg-40603745
PGLA Avexa ® ® 12/08 #msg-34341452
NUVO ABIO ® ® 9/08 #msg-32420015
NOVC TSPT ® ® 9/08 #msg-31869987
SNUS OGXI ® ® 5/08 #msg-29604972
‡ Relative to “unaffected” share price in cases where
a buyout offer or auction was made public; excludes
CVRs unless otherwise specified.
* Adjusted for cash/debt on acquired company’s balance
sheet; excludes CVRs unless otherwise specified.
® Reverse merger; premium not calculable.
c.v. No premium to cash value of acquired company.
f Premium relative to “unaffected” closing price on 12/1/23
g Merged co named Ayala but trades under ADXS symbol.
h For 43% of company not already owned.
j Relative to “unaffected” closing price on 1/16/18.
k Premium relative to 3/30/16 close.
m Merged company to be named Novelion.
n Premium relative to 2/24/15 (before leak of buyout bidding war).
p Premium relative to 8/18/14 (before speculation re AGN takeover).
q Premium relative to 4/10/14 (before Pershing Sq accumulation). After the merger, Actavis (ACT) renamed itself Allergan (AGN).
s Premium excludes contingent fees and is calculated from
12/13/13 close, the day before ENDP offer.
t For 42% of company not already owned.
u Includes $1.7B assumption of debt; premium relative to
3/27/12 close, when Bloomberg reported BMY bid. AZN pays
BMY $3.4B to put AMLN’s portfolio into 50/50 JV.
v Excluding CVR of $4-14/sh; premium relative to 7/22/10 close.
w For 44% of DNA not already owned.
x Price includes entire deal in three stages; 17% premium is the
blended avg price of NVS’ purchases ($164) relative to ACL’s market
price 4/4/08 immediately prior to announcement of first stage of deal.
y Includes $0.45/sh of contingent payments.
z Liquidated by Deerfield following failed merger with Archemix.
LLY acquires MORF for $57/sh cash—a 79% premium to Friday’s closing price:
https://finance.yahoo.com/news/lilly-acquire-morphic-improve-outcomes-104500467.html
MORF’s lead drug is MORF-057, an oral small-molecule drug in phase-2 for UC and Crohn’s disease.
The nominal deal value is $3.2B.
Re: SOLV-MDWD
My understanding from above quote is that the offer was indeed done.
GLP- only approved for TD2 (and obesity). True, and at a basic level, this makes sense since GLP-1 mainly encourages the pancreas to produce more insulin and in TD1, the pancreas are not functioning. But apparently there are studies using GLP-1 in TD1 and off label use. Likely better sources but here is one discussion;
https://t1dexchange.org/glp-1-therapy-type-1-diabetes/
Is_this_strictly_for type 2 diabetes, versus type 1?
Ligand to acquire APEIRON Biologics AG for $100M cash
Ligand Pharmaceuticals announced that it has entered into a definitive agreement to acquire APEIRON Biologics AG, which holds royalty rights to QARZIBA or dinutuximab beta for the treatment of high-risk neuroblastoma, for $100M in cash. In addition, Ligand will pay APEIRON shareholders additional consideration based on future commercial and regulatory events, including up to $28M if QARZIBA royalties exceed certain predetermined thresholds by either 2030 or 2034, respectively. APEIRON is a private biopharmaceutical company based in Vienna, Austria. ..."The addition of QARZIBA to our commercial royalty portfolio further supports our growth strategy to invest in high-value medicines that deliver significant clinical value and generate Under the terms of the agreement, which has been unanimously approved by both the Board of Directors at Ligand and APEIRON's Supervisory Board, Ligand will acquire all the outstanding shares of APEIRON for $100 million in cash at closing.
Ligand will also pay APEIRON shareholders additional consideration based on future commercial and regulatory events, including up to $28 million if QARZIBA royalties exceed certain predetermined thresholds by either 2030 or 2034, respectively. The transaction is subject to a 30-day shareholder objection period and other customary closing conditions and is expected to close in July 2024. Concurrently, Ligand is also entering into a stock purchase agreement whereby it has committed to investing up to $4 million in invIOs Holding AG, a privately held spin-off of APEIRON. The proceeds will help finance the research and development of three innovative early-stage immuno-oncology assets. APEIRON is entitled to royalties and milestone payments on these assets which will further expand Ligand's development stage portfolio. This transaction is expected to close in July 2024. Financial Guidance Update [b]The APEIRON acquisition will be immediately accretive to Ligand's earnings per share by approximately $1.00 on an annualized basis. Ligand is increasing its 2024 revenue guidance to be in the range of $140 million to $157 million previously $130 million to $142 million and is raising core adjusted EPS guidance to $5.00 to $5.50 previously $4.25 to $4.75 . Royalties are now expected to range from $100 million to $105 million previously $90 million to $95 million . Guidance for sales of Captisol is unchanged at $25 million to $27 million and contract revenue is now expected to range from $15 million to $25 million, previously $15M to $20M .
Read more at:
https://thefly.com/n.php?id=3942040
This is company's CEO comment in Goog auto translation:
Ofer Gonen, CEO of Medivand, said in response: "The company's policy is not to respond to rumors. We are focused on building a long-term future for Medivend and ensuring the supply of essential medicines to millions of patients around the world. We have Nexobride, a drug for severe burns that saves lives, and we see its importance, especially in the difficult days since October 7. In addition, we have Ascarax, a chronic wound healing drug that is in advanced development. This is the only drug in the world that threatens Santyl's dominance."
Is_this_strictly_for type 2 diabetes, versus type 1?
I.e., T2D Implies Type two diabetes, often associated with obese patients, as opposed to type one diabetics, who are born that way, and have to start taking insulin from a very young age.
I’m told that as young children they are given a banana or an orange to start stabbing with a needle so they can get used to doing it into their own skin in order to deliver insulin.
That, plus watching what you eat from childhood, can’t be a lot of fun.
the propensity score matching didn't control for severity of T2D
Thanks, Midas. Is there any hint about who is the source for Yoram Gavizon's report?
I am long SOLV as a consequence of having owned 3M.
Best critique I've seen. TLDR: the propensity score matching didn't control for severity of T2D (eg duration of disease, other treatments, HbA1c) and Ozempic isn't first line treatment. So by definition the more severe diabetics were more likely to get Ozmpic
DO GLP-1 Agonists Really Cause Eye Disease
— Ed Livingston (@ehlJAMA) July 7, 2024
There has been a huge amount of press about a report showing an association between the use of GLP-1 agonists and Nonarteritic anterior ischemic optic neuropathy (NAION)https://t.co/unSdVTE6Zs
Because of it being heavily promoted by… pic.twitter.com/fHeVn9LBJr
Yoram Gavizon - A reputable reporter for the financial newspaper
Medivend, which developed a product for healing wounds, became an attractive target for acquisition
A successful trial of the flagship product that showed superiority over the leading product for healing chronic wounds, fundamental changes in insurance policy in the US and the product's success in treating the burns of the war-wounded in Gaza - all of these made Medivand an attractive asset for wound healing companies ¦ The American Solventum is interested in acquiring Medivand at a premium of 118% at its current price
Yoram Gavizon
July 4, 2024
JAMA paper - NAION risk associated with GLP-1 meds so it’s reasonable to be skeptical of the findings
I don't know if you are skeptical or not but you did say it is reasonable to be skeptical. I certainly am skeptical of this. NAION risk didn't show up according to Novo in any of their much larger trials. This JAMA paper cited trial was relatively small in comparison to the prior NOVO studies. Also, this was a single center study where investigator bias may have shown up.
MDWD—The Hebrew–>English translation failed when I clicked on your link. Who, exactly, is reporting that SOLV offered to acquire MDWD at a 118% premium? TIA
https://www-themarker-com.translate.goog/markets/2024-07-04/ty-article/.premium/00000190-7990-db4b-ab98-7ddee62e0000?_x_tr_sl=iw&_x_tr_tl=en&_x_tr_hl=en&_x_tr_pto=wapp&_x_tr_hist=true
Mediwound which developed a product for healing wounds, became an attractive target for acquisition
A successful trial of the flagship product that showed superiority over the leading product for healing chronic wounds, fundamental changes in insurance policy in the US and the product's success in treating the burns of the war-wounded in Gaza - all of these made Mediwound an attractive asset for wound healing companies ¦ The American Solventum is interested in acquiring Mediwound at a premium of 118% at its current price
TheMarker is an Israeli financial newspaper:
https://www.themarker.com/markets/2024-07-04/ty-article/.premium/00000190-7990-db4b-ab98-7ddee62e0000
Yes it does:
Vericel Enters into Exclusive License Agreement with MediWound for North American Rights to
NexoBrid, a Biological Orphan Product for Debridement of Severe Thermal Burns
May 7, 2019 at 1:59 AM EDT
Thanks for that link to a MDWD rumor(?). We hold shares of 3M, SOLV, as well as ~ 15k shares of VCEL….I could be wrong, but doesn’t VCEL have some exclusive rights to MDWD burn therapy IP at least in the U.S.?
MDWD +35% on rumored buyout interest from SOLV:
https://invezz.com/news/2024/07/05/mediwound-stock-soars-on-solventum-takeover-interest/
The above article does not give the source of the rumor.
SOLV is the recent (4/1/24) healthcare spinoff from 3M (#msg-174387294).
Also fewer adverse events than BCMA (from memory - soooo…)?
Morgan Stanley says impact to Lilly GLP-1 opportunity from NAION link 'very low'
cabotegravir is approved for Prep already, and also superior efficacy to oral Prep in studies. However it is every other month not every 6 months, there were some breakthrough infections, and it is associated with more discomfort. You also have the theoretical risk of integrase resistance which is currently the backbone of first line therapy for most patients.
GSK will probably talk about their longer acting cabotegavir formulation, they are also working on subcutaneous, but I do think GILD will retain the clear edge here for those that do want long acting prep
new way to prevent HIV delivers dramatic results
#msg-174632278
https://www.npr.org/sections/goats-and-soda/2024/07/03/g-s1-7988/hiv-prevention-drug-clinical-trial
For over a decade, taking a pill like Truvada every day has been the standard of care for HIV prevention efforts.
In clinical trials, this type of preventive drug, called pre-exposure prophylaxis (PrEP), can be 99% effective in stopping new HIV infections from sex. In the real world, however, that is not always the case.
People don’t always take their pills. In a study in South Africa, women said they felt there was a stigma to the pill —- a sexual partner might assume they’re taking it because they already have HIV or because they have other partners.
Now a new trial —- called PURPOSE 1 —- points the way to a new preventive strategy —- a twice yearly injection of a drug called lenacapavir. The trial was sponsored by Gilead Sciences, the California-based maker of the drug.
In this double-blind, randomized study of 5,300 cisgender women in South Africa and Uganda, 2,134 got the injection and the others took one of two types of daily PrEP pills. The trial began on August 2021 and, so far, not a single woman who received the injections has contracted HIV. The participants who received either of the oral PrEP options, Truvada and Descovy, had infection rates of about 2% — consistent with the infection rates of oral PrEP in other clinical trials.
These results were significant enough for the Data Monitoring Committee —- an independent group of experts appointed to assess the progress of clinical trials —- to recommend that Gilead halt its blinded trial and offer lenacapavir to all study participants. On June 20, Gilead announced these results, and now, all participants can choose to receive the injection.
Morgan Stanley says impact to Lilly GLP-1 opportunity from NAION link 'very low'
Morgan Stanley notes that following a JAMA publication discussing an increased risk of nonarteritic anterior ischemic optic neuropathy, or NAION, in patients who received Novo Nordisk's (NVO) semaglutide that the firm received some inbound questions on the GLP-1 safety profile. In an accompanying editorial in JAMA discussing the study, the author noted that at this time the potential risk of NAION should not deter the use of GLP-1s in people with type 2 diabetes or obesity, notes the analyst, who also notes Novo Nordisk has commented that the risks aren't something they have seen in their extensive clinical trial programs or pharmacovigilance surveillance, which is why it is not noted in the label.
From an Eli Lilly (LLY) perspective, any link between NAION and GLP-1s remains subject to further exploration, but at this point the firm sees the risk and potential impact to the commercial opportunity as "very low," the analyst tells investors. The firm maintains an Overweight rating and $1,023 price target on Eli Lilly shares.
Read more at:
https://thefly.com/n.php?id=3941588
To a large extent , propensity score matching should have corrected for obesity/ BMI though diabetic control did not seem to be one of the variables matched in the algorithm according to the abstract.
To a large extent , propensity score matching should have corrected for obesity/ BMI though diabetic control did not seem to be one of the variables matched in the algorithm according to the abstract.
A comment to the JAMA article by Howard Krauss quotes an important possibled confounder from the article, which is, in possible that sicker or more obese patients were more likely to be presribed semaglutide and it was that condition that resulted in the increased NAION rate:
Importantly, Hathaway and colleagues note, “our retrospective study does not allow inquiry into potential biases related to decisions about which patients were prescribed semaglutide,” such that if one were to hypothesize that it was the sicker, or more poorly-controlled diabetics, or heavier obese patients, on average, who had been prescribed semaglutide, it then becomes difficult to incriminate the semagludtide as the “culprit,” rather than severity of the underlying disease itself. Hathaway et al write, “our survival analyses of both cohorts expose the greatest risk of NAION to be within the first year following prescription of semaglutide, a temporal association that supports a potential drug-induced risk of NAION,” but, on the other hand, it may just as well be that the declining risk over time is due to efficacy of semaglutide in having promoted weight loss and better control of diabetes, with attendant reduction of risk posed by the underlying diseases themselves.
BTW - the biggest set of adverse events was gall bladder related (inflammation and stones)
Followers
|
1525
|
Posters
|
|
Posts (Today)
|
2
|
Posts (Total)
|
252965
|
Created
|
11/14/02
|
Type
|
Free
|
Moderator DewDiligence | |||
Assistants Biowatch |
Biotech Values is a forum for discussing
all facets of biotech investing with an emphasis
on fundamental analysis and avoiding scams.
We generally do not discuss microcap stocks.
Compilations
Biotech Buyouts/Premiums
Oral Weight-Loss Drugs
Biotech-Newbie Misconceptions (see Reply chain)
Biotech Abbreviations and Acronyms
'Way Back' Archive (Greatest Hits 2003-2009)
Posts Today
|
2
|
Posts (Total)
|
252965
|
Posters
|
|
Moderator
|
|
Assistants
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |